Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
220.1 ^USD	+1.33%		+7.22%	-4.89%

17/05	Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing	MT
10/05	B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating	MT

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

September 26, 2023 at 01:32 am IST

Madrigal Pharmaceuticals, Inc. (the ?Company?) reported that Remy Sukhija, who has served as the Company?s Chief Commercial Officer since April of 2020, is leaving the Company to pursue other opportunities.

Latest news about Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing	17/05	MT
B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating	10/05	MT
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating	09/05	MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	07/05	MT
Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell	07/05	MT
Transcript : Madrigal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024	07/05
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective	22/04	MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target	22/04	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing	11/04	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing	11/04	MT
Madrigal Pharmaceuticals Says Rezdiffra Available in US	09/04	MT
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis	09/04	CI
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing	04/04	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing	04/04	MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing	04/04	MT
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating	20/03	MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	19/03	MT
Madrigal Pharmaceuticals Prices $600 Million Public Offering	19/03	MT
Madrigal Pharmaceuticals Starts $500 Million Public Offering	19/03	MT
Madrigal plans $500 million fund raising to prepare for NASH drug launch	19/03	RE
Madrigal commences $500 million public offering of common stock	19/03	RE
North American Morning Briefing : Investors -2-	18/03	DJ
TD Cowen Adjusts Madrigal Pharmaceuticals' Price Target to $390 From $349, Maintains Outperform Rating	15/03	MT
Madrigal Pharmaceuticals Gets Added Boost with Rezdiffra Nod From FDA, B. Riley Says	15/03	MT

Chart Madrigal Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

220.1 USD

Average target price

363.9 USD

Spread / Average Target

+65.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MADRIGAL PHARMACEUTICALS, INC.	-4.89%	4.69B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-2.68%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs